IGF1R and neoplasm: It was inferred that trastuzumab might ease the side-effect of LMAb1 in vivo with unknown reason, for mice treated with LMAb1 only didn’t contribute to obvious longer survival time, although the tumor volume was indeed smaller than control group(s); besides, we also evidenced preliminarily that the mechanism of antibody included the inhibition of IGF-1R and downstream MAPK, AKT pathway activation (Figure 4).